Nirsevimab in Infants: The Cost of Changing the Paradigm

Department of Pediatric Pulmonology, Clínica MEDS, Santiago, Chile

*Corresponding author: Alberto Vidal, MD, Department of Pediatric Pulmonology, Clínica MEDS, Avenida José Alcalde Délano 10581, Lo Barnechea, Santiago, Chile, Email: [email protected].

Received Date: March 18, 2024

Published Date: April 02, 2024

Citation: Vidal A. (2024). Nirsevimab in Infants: The Cost of Changing the Paradigm. Mathews J Pediatr. 9(1):35.

Copyrights: Vidal A. © (2024).

ABSTRACT

Nirsevimab is an IgG1-type monoclonal antibody approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the prevention of RSV-LRTI in preterm, late preterm, and term infants. Subsequent studies have reported that the efficacy of nirsevimab could be extrapolated to extremely premature children (< 29 weeks gestational age), with chronic lung disease and congenital heart disease. The cost-effectiveness of immunization with nirsevimab appears to be higher than standard care and palivizumab. Despite strong evidence, most countries that have implemented mass immunization programs with nirsevimab are high-income and concentrated in the northern hemisphere.

Keywords: Nirsevimab, Prevention, Respiratory Syncytial Virus, Cost-Effectiveness, Lower Respiratory Tract Infection.